Verona Pharma surges as lung disease therapy meets main goal in study

Verona Pharma

09/08/2022 14:40

** U.S.-listed shares of Verona Pharma PLC  VRNA.O  more
than double to $14.12 in morning trade 
    ** UK-based biopharm co says its experimental lung disease
therapy ensifentrine met main goal in a late-stage study, with
data showing statistically significant improvements in key
measures of lung function across all groups  urn:newsml:reuters.com:*:nGNX8f2VYv
    ** Co is developing ensifentrine as a potential treatment
for chronic obstructive pulmonary disease (COPD), which causes
airflow blockage and breathing-related problems
    ** Adds that in study, ensifentrine was well tolerated with
safety results similar to that of placebo
    ** VRNA plans to submit marketing application for
ensifentrine to the U.S. health regulator in H1 2023 
    ** Co also reports net loss of $17.8 mln for Q2 2022 vs loss
of $22.1 mln last year  urn:newsml:reuters.com:*:nGNX6LMjz3    
    ** As of last close, VRNA up 3.4% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))